Semaglutide, sold as Wegovy, is the most reasonable first option for weight loss when minimizing nausea and other gastrointestinal side effects is the main priority. Comparative research generally finds less nausea with semaglutide than with tirzepatide, sold as Zepbound, although the difference is not definitive and individual responses vary. The 2025 Wegovy FDA label reports gastrointestinal adverse reactions in 73% of adults in weight-loss trials.
For type 2 diabetes, dulaglutide, sold as Trulicity, often has the lowest gastrointestinal side-effect burden among commonly used injectable GLP-1 medicines. Trulicity is approved for diabetes treatment, not specifically for weight loss.
Best Choice by Treatment Goal
| Treatment goal | Most tolerability-focused option | Important qualification |
|---|---|---|
| Weight loss | Semaglutide, Wegovy | Comparative research suggests less nausea than tirzepatide, but Wegovy can still cause significant gastrointestinal symptoms. |
| Type 2 diabetes | Dulaglutide, Trulicity | Often shows a lower gastrointestinal risk in comparative analyses, but it is not a dedicated weight-loss medication. |
| Avoiding daily injections | Semaglutide, tirzepatide, or dulaglutide | These are weekly injections, but weekly treatment does not guarantee fewer side effects. |
| Avoiding the highest gastrointestinal burden | Usually avoid starting with liraglutide unless there is a specific reason | Saxenda's FDA label reports substantial rates of nausea and other gastrointestinal reactions. |
How the Main GLP-1 Medicines Compare
Most people asking about side effects mean nausea, vomiting, diarrhea, constipation, bloating, or abdominal pain. These are the most common problems reported with GLP-1 medicines and related drugs.
Semaglutide: Wegovy and Ozempic
Compared with tirzepatide, semaglutide has a relatively favorable tolerability signal in obesity-focused comparative research. That does not make it free of side effects. The FDA's 2025 Wegovy label reports gastrointestinal adverse reactions in 73% of adults in weight-loss trials. Nausea occurred in 44%, vomiting in 25%, and diarrhea in 30%. About 4.3% permanently stopped treatment because of a gastrointestinal reaction.
Semaglutide is a reasonable option when weight loss is the goal and reducing gastrointestinal symptoms matters more than pursuing the greatest average weight loss.
Tirzepatide: Zepbound and Mounjaro
Tirzepatide activates both the GIP and GLP-1 receptors, so it is technically a dual GIP/GLP-1 medicine rather than a GLP-1-only drug.
In an obesity-focused network meta-analysis, tirzepatide ranked above semaglutide for nausea risk. The FDA Zepbound label reports gastrointestinal adverse reactions in 56% of patients across the 5 mg, 10 mg, and 15 mg doses. Nausea occurred in 25% to 29% of patients, vomiting in 8% to 13%, and diarrhea in 19% to 23%. These reactions were most common during dose escalation and generally decreased over time.
Zepbound may produce greater average weight loss than Wegovy, but it is not the clearest first choice when avoiding nausea is the main priority.
Dulaglutide: Trulicity
Dulaglutide is often one of the better-tolerated injectable options for people with type 2 diabetes. In a 2026 network meta-analysis, dulaglutide had a lower estimated absolute increase in gastrointestinal adverse events than semaglutide, liraglutide, and tirzepatide.
In FDA trials using the 1.5 mg dose, Trulicity caused nausea in 21.1% of patients, diarrhea in 12.6%, and vomiting in 12.7%. These figures come from diabetes trials, so they should not be compared directly with weight-loss trial percentages for Wegovy or Zepbound. The patient populations, doses, and study methods differ.
Liraglutide: Saxenda and Victoza
Liraglutide is generally less attractive when gastrointestinal tolerability is the main concern. The Saxenda FDA label reports gastrointestinal disorders in about 68% of adults, with nausea occurring in 39%. Gastrointestinal reactions caused treatment discontinuation in 6.2% of adults.
Saxenda also requires a daily injection. Wegovy, Zepbound, and Trulicity are administered weekly.
Why Is There No Single GLP-1 With the Fewest Side Effects?
There is no universal least side-effect GLP-1 because trial averages do not predict how one person will respond. Side effects are influenced by:
- The starting dose and speed of dose increases
- The maintenance dose
- Whether you have reflux, constipation, irritable bowel syndrome, or gastroparesis
- Other medications, especially insulin or sulfonylureas
- Your history of gallstones, pancreatitis, or kidney disease
- How much weight you lose and how quickly you lose it
Trial percentages also cannot be ranked perfectly because each FDA label comes from a different study. For example, the 73% gastrointestinal-event rate in a Wegovy trial should not be treated as directly comparable with the 56% rate in a Zepbound trial.
How Can You Reduce GLP-1 Side Effects?
The main tolerability strategy is slow dose escalation under medical supervision. The FDA labels for Wegovy and Zepbound state that nausea, vomiting, and diarrhea occur most often during dose increases and tend to decrease over time.
Other steps include:
- Do not increase the dose while symptoms are still significant.
- Eat smaller meals and stop when you feel full.
- Avoid large, high-fat meals if they worsen nausea or reflux.
- Drink enough fluid, especially if vomiting or diarrhea occurs.
- Ask the prescriber about holding the dose, reducing the dose, or switching medications if symptoms persist.
What Safety Limitations Matter?
All of these medicines can cause gastrointestinal symptoms. Serious complications can include dehydration-related kidney injury, gallbladder disease, pancreatitis, severe gastrointestinal reactions, and allergic reactions. Low blood sugar becomes more likely when a GLP-1 medicine is combined with insulin or a sulfonylurea.
GLP-1 medicines also carry a boxed warning concerning thyroid C-cell tumors. They should not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. A clinician should also review treatment carefully if you have severe gastroparesis, previous pancreatitis, significant gallbladder disease, or are pregnant or planning pregnancy.
Seek urgent medical care for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, yellowing of the skin or eyes, facial or throat swelling, or trouble breathing.
Bottom Line
- For weight loss and the lowest likely nausea burden: discuss semaglutide, Wegovy, first.
- For type 2 diabetes and gastrointestinal tolerability: dulaglutide, Trulicity, often has the most favorable profile.
- Tirzepatide, Zepbound, can produce more weight loss on average but may cause more gastrointestinal symptoms.
- Liraglutide, Saxenda, tends to have a higher gastrointestinal burden and requires daily injections.
The best-tolerated GLP-1 is usually the medication that reaches a useful result at the lowest dose you can comfortably maintain.